BIIB vs PRAX
BIIB: Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease. PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms.
Side-by-side fundamentals
| Metric | BIIB | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $197.74 | $312.10 | |
| Market cap as of 2026-07-23 | $29.8B | $8.7B | |
| P/E as of 2026-07-23 | 21.75 | n/a | |
| PEG as of 2026-07-23 | 10.24 | -0.95 | PRAX lower |
| Net margin as of 2026-07-23 | +13.8% | -2137.5% | BIIB higher |
| Gross margin as of 2026-07-23 | +75.5% | n/a | |
| Operating margin as of 2026-07-23 | +17.5% | -2340.3% | BIIB higher |
| ROE as of 2026-07-23 | +7.5% | -43.0% | BIIB higher |
| ROA as of 2026-07-23 | +4.7% | -40.2% | BIIB higher |
| Debt / equity as of 2026-07-23 | 0.34 | 0.00 | PRAX lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Beta as of 2026-07-23 | 0.16 | 2.80 | |
| 1-year return as of 2026-07-22 close | +54.7% | +476.3% | PRAX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.